Importantly, we show that P22 binding to the sialic acid-binding pocket of CD33 can increase uptake of the toxic Aβ42 peptide into microglial cells, and hence CD33 is a promising target for structure-based drug discovery for the treatment of AD. This evidence concerns the gene CD33 and Alzheimer disease.